NEW YORK--(BUSINESS WIRE)--PWNHealth (PWN), a national clinician network and leading provider of diagnostic testing solutions and telehealth services, today announced the expansion of its clinical consultation and oversight services to aid national COVID-19 vaccination efforts. This new program will build upon PWN's ongoing work to mitigate the impact of the COVID-19 pandemic, which includes support of more than 14 million COVID tests since March 2020.
As the U.S. scales its vaccination plans, PWN will now offer recipients a host of resources and counsel before, during and after their appointment. PWN clinicians will answer post-vaccination questions, work with participants to schedule their second shots, and monitor, report and triage symptoms or adverse events.
This month, PWN began rolling out its COVID-19 vaccination support program in collaboration with CIC Health, a Cambridge, Mass.-based health tech company offering COVID-19 testing and vaccination services. CIC Health has been selected by the Commonwealth of Massachusetts to operate New England's first mass vaccination site at Gillette Stadium in Foxborough. The site plans to upscale from administering 300 daily shots to 5,000 in the coming weeks. PWN’s COVID-19 vaccination support program is now available nationwide.
"Vaccination remains the strongest opportunity to end the pandemic that's wreaked havoc across our nation during the last year, and we are thrilled to assist the teams and processes that are bringing these great measures to the public," said Sanjay Pingle, CEO of PWNHealth.
PWN's vaccination program will incorporate CDC-supported technologies to empower personalized check-ins and streamline side effect reporting with recipients. Additionally, PWN will capture and report adverse reactions from the immunization to the Vaccine Adverse Events Reporting System (VAERS).
“There is a lot of fear, misinformation and uncertainty around vaccines. PWN’s clinicians extend much needed clinical support into the home, helping answer questions, assuage fears and, when appropriate, triage to in-person care. We can also provide reminders around getting back to their secondary vaccination and confirmatory testing,” said Bill Paquin, Chief Commercial Officer of PWNHealth.
In September 2020, PWN launched its COVID-19 testing dashboard to highlight key testing trends among local and national demographics. To date, PWN-supported PCR and antigen testing programs have returned a 6.5 percent positive rate. Further, the company has provided support and clinical guidance to more than 670,000 Americans with a positive or indeterminate result since the start of the pandemic.
“PWN’s long-standing experience providing expanded access to diagnostic testing and remote care, coupled with the role we play in national COVID-19 testing, provides us with great insight into how to scale these programs while maintaining high quality. At the core of testing and vaccination, there is a need for access to the clinical support and guidance people want and ultimately need,” said Doug Elwood, MD, Chief Medical Officer of PWNHealth.
For more information about PWNHealth and its complete diagnostic testing solutions portfolio, visit pwnhealth.com.
About PWNHealth
PWNHealth (PWN) is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth. Our solutions provide the clinical, legal, and technological framework to facilitate population-scale testing across key healthcare markets in all 50 states and Puerto Rico. PWN is supporting more than 45 national COVID-19 testing programs and have managed more than 14 million COVID-19 tests through our platform. We believe that empowering people with convenient access to clinically actionable testing has the power to change lives, improve outcomes, and create a healthier world. PWN is backed by leading growth equity firms Spectrum Equity and the Blue Venture Fund (BVF). For more information, visit pwnhealth.com. Follow us on Twitter, LinkedIn and Medium.
